Wellington Management Group
TCRX icon

Wellington Management Group’s TScan Therapeutics TCRX Stock Holding History

Wellington Management Group’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-132,895
Closed -$404K – 2045
2024
Q4 		$404K Buy
132,895
+6,550
+5% +$29.7K ﹤0.01% 1854
2024
Q3 		$629K Buy
126,345
+35,404
+39% +$214K ﹤0.01% 1787
2024
Q2 		$532K Buy
+90,941
New +$716K ﹤0.01% 1776
2021
Q4 		– Sell
-139,566
Closed -$1.16M – 2291
2021
Q3 		$1.16M Buy
+139,566
New +$1.29M ﹤0.01% 1771

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Wellington Management Group's TCRX Position: Q1 2025 in Review

Wellington Management Group sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 132,895 shares — an estimated $404K sold.

Wellington Management Group first reported a position in TCRX in Q3 2021 and held it in 4 quarters. The position peaked at $1.16M in Q3 2021. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • Wellington Management Group reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wellington Management Group sold 132,895 TScan Therapeutics shares in Q1 2025, an estimated $404K.
  • Wellington Management Group first reported a position in TScan Therapeutics in Q3 2021 and held it in 4 quarters.
  • Wellington Management Group's TScan Therapeutics position peaked at $1.16M in Q3 2021.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on Wellington Management Group's 13F filing for Q1 2025, filed 13 May 2025.